SCHEMBL4052382

SCHEMBL4052382

CCn1nc(-c2cccs2)c(C(=O)OCc2ccccc2)c(Nc2cncc3ccccc23)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.40
ALDH1A1 P00352 5/20 0.37
CYP1A2 P05177 3/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
HIF1A Q16665 2/20 0.37
HSD17B10 Q99714 2/20 0.37
HTT P42858 1/20 0.36
PDE4B Q07343 1/20 0.36
TRPV1 Q8NER1 5/20 0.35
CYP3A4 P08684 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
ELANE P08246 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051184 0.95 HTT (0.39) ADORA1ALDH1A1CYP1A2CASP1CASP7
SCHEMBL4054290 0.94 ADORA1 (0.38) ADORA1ALDH1A1CYP1A2CASP1CASP7
SCHEMBL4049579 0.93 ADORA1 (0.38) ADORA1ALDH1A1HTTPDE4BTRPV1
SCHEMBL4053146 0.92 ADORA1 (0.43) ADORA1ALDH1A1CASP1CASP7HIF1A
SCHEMBL4059427 0.90 ADORA1 (0.41) ADORA1ALDH1A1CYP1A2CASP1CASP7
SCHEMBL4057121 0.89 ADORA1 (0.40) ADORA1ALDH1A1CYP1A2CASP1CASP7
SCHEMBL4057540 0.89 ADORA1 (0.45) ADORA1ALDH1A1CYP1A2CASP1CASP7
SCHEMBL4051228 0.88 ADORA1 (0.40) ADORA1ALDH1A1CASP1CASP7HIF1A
SCHEMBL4050813 0.87 PDE4B (0.39) ADORA1ALDH1A1HTTPDE4BTRPV1
SCHEMBL4051583 0.87 ADORA1 (0.39) ADORA1ALDH1A1CYP1A2CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029996-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-29 US claimed
US-20090029996-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-29 US disclosed
EP-1781621-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Laboratorios Almirall, S.A. (ES) 2007-05-09 EP disclosed
WO-2005123693-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029996-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE4B ADORA1 311/4885ALDH1A1 324/4885CYP1A2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.